6,898 results match your criteria Overactive Bladder - Treatment


Association of lower urinary tract symptoms and diuretic adherence.

Low Urin Tract Symptoms 2022 Jun 23. Epub 2022 Jun 23.

Division of Urology, Department of Surgery, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Objective: To assess whether more severe urinary symptoms and poorer quality of life among patients on diuretic therapy are associated with decreased adherence to the diuretic regimen.

Methods: Participants were recruited via ResearchMatch.org and sent a REDCap survey. Read More

View Article and Full-Text PDF

Impact of Mirabegron Administration on the Blood Pressure and Pulse Rate in Patients with Overactive Bladder.

Medicina (Kaunas) 2022 Jun 19;58(6). Epub 2022 Jun 19.

Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan.

To determine changes in the blood pressure (BP) and pulse rate (PR) before and after the administration of mirabegron in real-world clinical practice for patients with overactive bladder (OAB). This study was conducted in patients newly diagnosed with OAB. Before and 12 weeks after mirabegron treatment, we evaluated the effects on BP and PR. Read More

View Article and Full-Text PDF

Effects of β3 Agonists and Anticholinergic Drugs on Defecation in Patients With Overactive Bladder.

In Vivo 2022 Jul-Aug;36(4):1847-1853

Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Background/aim: In clinical practice, constipation is one of the most frequent adverse events caused by drugs for overactive bladder (OAB). The occurrence of constipation greatly deteriorates the patient's quality of life. The aim of the study was to evaluate and compare the effects of three commonly used β3 agonists and anticholinergic drugs on the defecation status in patients with OAB. Read More

View Article and Full-Text PDF
February 2022

Solifenacin Treatment After Intradetrusor Injections With Botulinum Toxin in Patients With Neurogenic Detrusor Overactivity.

Am J Ther 2022 Jun 21. Epub 2022 Jun 21.

Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.

Background: Neurogenic detrusor overactivity (NDO) is treated with antimuscarinics as first-line treatment. For patients with contraindications or unresponsive, intradetrusor injections with botulinum toxin (BoNT) are a safe and effective but expensive option.

Study Question: Our study evaluated whether adding solifenacin to the intradetrusor injection of BoNT A could boost the effect of BoNT in patients with NDO due to multiple sclerosis or spinal cord injury refractory to antimuscarinics alone and/or lead to less frequent injections. Read More

View Article and Full-Text PDF

Aqua: A new questionnaire assessing anticholinergic side effects in neurogenic population (Aqua: Anticholinergic side effects questionnaire).

Prog Urol 2022 Jun 18. Epub 2022 Jun 18.

Sorbonne université, GRC 001, GREEN Groupe de Recherche Clinique en Neuro-Urologie, AP-HP, hôpital Tenon, 4, rue de la Chine, 75020 Paris, France; Service de Neuro urologie et explorations urodynamiques, hôpital Tenon, 4, rue de la Chine, 75020 Paris, France.

Aims: Validate a new questionnaire to assess the side effects secondary to anticholinergics in neurogenic population suffering from Adult neurogenic lower urinary tract dysfunction (ANLUTD).

Methods: We conducted a prospective, monocentric study in a Neuro-urology Department of a University Hospital between February 2015 and April 2020. To allow a full psychometric validation of a questionnaire, the study protocol included 3 steps: qualitative interviews, feasibility study and validation study. Read More

View Article and Full-Text PDF

Subjective Outcome after Discontinuation of Botulinum Toxin-A Detrusor Injection for Lower Urinary Tract Disorders: The Majority Suffers!

Urol Int 2022 Jun 17:1-10. Epub 2022 Jun 17.

Department of Urology, Charité - University Hospital Berlin, Berlin, Germany.

Introduction: According to the EAU guidelines, botulinum toxin type A (BoNT-A) detrusor injections are one of the last options in the management of overactive bladder before opting for invasive surgery. So far, there have been no studies dedicated exclusively to such patients who have undergone this treatment and in whom this treatment has presumably failed. From the patient's point of view, there are questions regarding what reasons led to discontinuation, how patients perceive their BoNT-A treatment in hindsight, what further treatment do these patients receive, and how satisfied such patients are with their current situation. Read More

View Article and Full-Text PDF

Antagonism of α-adrenoceptors by β-adrenergic agonists: Structure-function relations of different agonists in prostate smooth muscle contraction.

Biochem Pharmacol 2022 Jun 15;202:115148. Epub 2022 Jun 15.

Department of Urology, University Hospital Munich, LMU Munich, Munich, Germany. Electronic address:

Effects of β-adrenergic agonists on prostate smooth muscle contraction are poorly characterized, although mirabegron is used for treatment of lower urinary tract symptoms. Off-target effects of several β-adrenergic agonists include antagonism of α-adrenoceptors. Proposed, but unconfirmed explanations include phenylethanolamine backbones, found in some β-adrenergic agonists and imparting interaction with catecholamine binding pockets of adrenoceptors. Read More

View Article and Full-Text PDF

Clinical and urodynamic findings before and after surgical repair of pelvic organ prolapse in women with lower urinary tract symptoms. A prospective observational study.

Urology 2022 Jun 14. Epub 2022 Jun 14.

Department of Urology, Ain Shams University, Cairo, Egypt. Electronic address:

Objectives: To investigate the association between urodynamic findings and lower urinary tract symptoms (LUTS) before and after surgical treatment of POP.

Methods: Seventy-four patients with stage II or more anterior POP associated with LUTS and eligible for surgical repair of POP were included in this prospective study. All cases had clinical evaluation and urodynamic testing (UDS) before and 6 months after surgical repair of POP. Read More

View Article and Full-Text PDF

TGR5 agonists induce peripheral and central hypersensitivity to bladder distension.

Sci Rep 2022 Jun 15;12(1):9920. Epub 2022 Jun 15.

Visceral Pain Research Group, College of Medicine and Public Health, Flinders Health and Medical Research Institute (FHMRI), Flinders University, Bedford Park, South Australia, 5042, Australia.

The mechanisms underlying chronic bladder conditions such as interstitial cystitis/bladder pain syndrome (IC/BPS) and overactive bladder syndrome (OAB) are incompletely understood. However, targeting specific receptors mediating neuronal sensitivity to specific stimuli is an emerging treatment strategy. Recently, irritant-sensing receptors including the bile acid receptor TGR5, have been identified within the viscera and are thought to play a key role in neuronal hypersensitivity. Read More

View Article and Full-Text PDF

Adverse events related to antimuscarinics and beta-3-agonist: "real-life" data from the Eudra-Vigilance database.

Minerva Urol Nephrol 2022 Jun 16. Epub 2022 Jun 16.

Department of Urology, Sant'Andrea Hospital, Rome, Italy.

Background: Antimuscarinic (AM) and beta-3-agonist (B3A) treatment are the standard first line pharmacological treatment used to manage overactive bladder (OAB) patients. Aim of our study was to analyze real-life data of adverse events related to AMs and B3A reported on Eudra-Vigilance (EV) database.

Methods: EV database is the system for managing and analyzing information on suspected adverse reactions to medicines which have been authorized or being studied in clinical trials in the European Economic Area (EEA). Read More

View Article and Full-Text PDF

Effectiveness and safety of acupuncture for overactive bladder: a randomised controlled trial (abridged secondary publication).

Hong Kong Med J 2022 Jun;28 Suppl 3(3):45-47

Yan Oi Tong - The Chinese University of Hong Kong Chinese Medicine Centre for Training and Research.

View Article and Full-Text PDF

Does metabolic syndrome influence the efficacy of mirabegron treatment in female patients with overactive bladder?

Int Urogynecol J 2022 Jun 14. Epub 2022 Jun 14.

Department of Urology, Kyorin University School of Medicine, 6-20-2 Shinkawa Mitaka-shi, Tokyo, 181-8611, Japan.

Introduction And Hypothesis: We aimed to determine whether the presence of metabolic syndrome (MS) affects the efficacy of mirabegron in treatment-naïve women with overactive bladder (OAB).

Methods: Women being treated with mirabegron 50 mg were allocated to MS and non-MS groups, and the efficacy of treatment of OAB was compared using the OAB symptom score (OABSS) and a 3-day voiding diary before and 12 weeks after starting treatment. The Wilcoxon signed-rank and Mann-Whitney U tests and multivariate logistic regression were used for statistical analyses, and a p-value < 0. Read More

View Article and Full-Text PDF

Selectivity and Maximum Response of Vibegron and Mirabegron for β-Adrenergic Receptors.

Curr Ther Res Clin Exp 2022 14;96:100674. Epub 2022 May 14.

Dermavant Sciences, Morrisville, North Carolina.

Background: The β-adrenergic agonists vibegron and mirabegron have shown favorable safety profiles and efficacy for the treatment of overactive bladder. However, β-adrenergic receptors are also found outside the bladder, which could lead to off-target activity.

Objective: This study assessed the selectivity of vibegron and mirabegron for β-adrenergic receptors and the maximal effect and potency for β-adrenergic receptors. Read More

View Article and Full-Text PDF

Transcutaneous Tibial Nerve Stimulation in the Management of Overactive Bladder: A Scoping Review.

Neuromodulation 2022 Jun 7. Epub 2022 Jun 7.

Discipline of Physiotherapy, University of Canberra, Canberra, Australian Capital Territory, Australia; Prehab, Activity, Cancer, Exercise, Survivorship Research Group, University of Canberra, Canberra, Australian Capital Territory, Australia. Electronic address:

Objective: Overactive bladder (OAB) is a condition that has physical, social, psychosocial, and financial impacts. Transcutaneous tibial nerve stimulation (TTNS) is a modality that stimulates the nerve root fibers of L5-S3, the same spinal segments of the parasympathetic nervous system as the bladder. This scoping review aims to identify current literature available on the feasibility and outcomes of TTNS as a first-line treatment option for OAB. Read More

View Article and Full-Text PDF

P2 purinergic receptor dysregulation in urologic disease.

Purinergic Signal 2022 Jun 10. Epub 2022 Jun 10.

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

P2 purinergic receptors are involved in the normal function of the kidney, bladder, and prostate via signaling that occurs in response to extracellular nucleotides. Dysregulation of these receptors is common in pathological states and often associated with disease initiation, progression, or aggressiveness. Indeed, P2 purinergic receptor expression is altered across multiple urologic disorders including chronic kidney disease, polycystic kidney disease, interstitial cystitis, urinary incontinence, overactive bladder syndrome, prostatitis, and benign prostatic hyperplasia. Read More

View Article and Full-Text PDF

Biofeedback-assisted pelvic floor muscle training and pelvic electrical stimulation in women with overactive bladder: A systematic review and meta-analysis of randomized controlled trials.

Neurourol Urodyn 2022 Jun 10. Epub 2022 Jun 10.

Department of Surgery, Division of Urology, Persahabatan General Hospital - Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.

Objective: This meta-analysis aims to compare biofeedback-assisted pelvic muscle floor training (PFMT) and pelvic electrical stimulation (ES) as an intervention group, with PFMT or bladder training (BT) as the control group, in women with an overactive bladder (OAB).

Method: PubMed, Cochrane, CINAHL, EMBASE, and Scopus were systematically searched for randomized controlled trials (RCTs) published up to November 2021. The RCTs were screened for our eligibility criteria and quality was evaluated using the Cochrane Risk Index of Bias tools. Read More

View Article and Full-Text PDF

Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial.

Int J Clin Pract 2022 13;2022:6475014. Epub 2022 Apr 13.

Urovant Sciences, Irvine, CA, USA.

Background: Overactive bladder (OAB) is characterized by urgency and frequency with (OAB wet) or without (OAB dry) urge urinary incontinence (UUI). In the phase 3 EMPOWUR trial, vibegron-a selective -adrenergic receptor agonist for the treatment of OAB-significantly improved daily number of urgency episodes and micturitions vs. placebo ( < 0. Read More

View Article and Full-Text PDF

Long-term clinical and urodynamic effectiveness of augmentation ileocystoplasty with supra-trigonal cystectomy in individuals with spinal cord injury.

World J Urol 2022 Jun 10. Epub 2022 Jun 10.

Neuro-Uro-Andrology Hospital Universitaire R.Poincare, AP-HP, 104 bvd R. Poincare, 92380, Garches, France.

Purpose: This study aimed to determine the long-term effectiveness of augmentation ileocystoplasty (AI) associated with supra-trigonal cystectomy on clinical and urodynamic variables, and the safety of the intervention in individuals with spinal cord injury (SCI).

Materials And Methods: Single-center, retrospective study of all patients with SCI who underwent AI with supra-trigonal cystectomy from January 1994, with a follow-up of more than 8 years. The primary outcome was the sustained long-term effectiveness of AI with supra-trigonal cystectomy on clinical and urodynamic variables. Read More

View Article and Full-Text PDF

Regarding the readability of online resources for third-line treatment of overactive bladder in the US population based on Werner et al's study.

Int Urogynecol J 2022 Jun 9. Epub 2022 Jun 9.

Department of Physical Medicine and Rehabilitation, Selcuk University School of Medicine, Konya, Turkey.

View Article and Full-Text PDF

Inhibition of Human Prostate and Bladder Smooth Muscle Contraction, Vasoconstriction of Porcine Renal and Coronary Arteries, and Growth-Related Functions of Prostate Stromal Cells by Presumed Small Molecule Gα Inhibitor, YM-254890.

Front Physiol 2022 23;13:884057. Epub 2022 May 23.

Department of Urology, University Hospital, LMU Munich, Munich, Germany.

Lower urinary tract symptoms (LUTS) involve benign prostatic hyperplasia (BPH) and overactive bladder (OAB). Standard-of-care medical treatment includes α-blockers and antimuscarinics for reduction of prostate and detrusor smooth muscle tone, respectively, and 5α-reductase inhibitors (5-ARI) to prevent prostate growth. Current medications are marked by high discontinuation rates due to unfavourable balance between efficacy and treatment-limiting side effects, ranging from dry mouth for antimuscarinics to cardiovascular dysregulation and a tendency to fall for α-blockers, which results from hypotension, due to vasorelaxation. Read More

View Article and Full-Text PDF

Asynchronous telehealth visits for the treatment of overactive bladder.

Menopause 2022 Jun 1;29(6):723-727. Epub 2022 Jun 1.

Massachusetts General Physicians Organization, Boston, MA.

Objective: Overactive bladder affects 17% of women, and adherence to treatment is notoriously low. The objective of this pilot study is to investigate the efficacy and feasibility of the use of asynchronous telehealth visits for the treatment of women with overactive bladder.

Methods: This is a pilot study of women who participated in the asynchronous telehealth program with a new diagnosis of overactive bladder presenting to the Massachusetts General Hospital from January of 2020 to March of 2021. Read More

View Article and Full-Text PDF

On-demand use of fesoterodine: a new paradigm for extended release antimuscarinics.

Int Urogynecol J 2022 Jun 6. Epub 2022 Jun 6.

Izmir Bozyaka Training and Research Hospital, Department of Urology, University of Health Sciences, Izmir, Turkey.

Introduction And Hypothesis: We aimed to compare on-demand and continuous use of fesoterodine 4 mg concerning efficacy and adverse effects.

Methods: A total of 100 patients who were diagnosed with non-neurogenic overactive bladder (OAB) syndrome were included in the study. All patients were evaluated with MMSE, ICIQ-SF, SEAPI quality of health and OAB-V8 questionnaires, at the beginning, 1st month and 4th month. Read More

View Article and Full-Text PDF

Patient perceived improvement and medication resumption rates after intradetrusor onabotulinumtoxina for idiopathic urgency urinary incontinence.

Int Urogynecol J 2022 Jun 3. Epub 2022 Jun 3.

Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44195, USA.

Introduction And Hypothesis: Intradetrusor onabotulinumtoxinA (BTX-A) is a third-line therapy for overactive bladder (OAB), however several gaps exist in periprocedural care. Prior studies have demonstrated BTX-A efficacy at 2-3 weeks, but there are limited data documenting when patients should begin to note symptom improvement. The primary aim of this study was to evaluate patient-reported temporal improvement in symptoms, with secondary aim to evaluate medication resumption rates, following initial BTX-A injection. Read More

View Article and Full-Text PDF

Does gabapentin impact response to anticholinergics for overactive bladder?

Int Urogynecol J 2022 Jun 1. Epub 2022 Jun 1.

Division of Female Pelvic Medicine and Reconstructive Surgery, Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Introduction And Hypothesis: It is unknown whether gabapentin modulates the therapeutic effect of anticholinergics (AC) in patients with overactive bladder. We hypothesized that pre-existing gabapentin use would improve response rates in these patients.

Methods: Female patients treated with AC between 2010-2018 were identified. Read More

View Article and Full-Text PDF

A Multi-Center, Randomized, Blind, Controlled Clinical Trial of the Safety and Efficacy of Micro Radio Frequency Therapy System for the Treatment of Overactive Bladder.

Front Med (Lausanne) 2022 12;9:746064. Epub 2022 May 12.

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

Purpose: The purpose of this study was to evaluate the efficacy and safety of low power micro radiofrequency (RF) therapy (μRFthera) through urethra in the treatment of overactive bladders (OAB) through a prospective, single-blind, placebo-controlled, multi-center clinical protocol.

Materials And Methods: One hundred and fourteen patients with refractory OAB were randomized at 2:1 ratio, treatment to control undergoing same procedures except only the micro-RF treatment group at turned "on" setting in energy. Bladder diaries recorded during the screening period (3 days before enrollment) and during follow-up period on week 1, 3, and 7, respectively. Read More

View Article and Full-Text PDF

Third-line therapy for overactive bladder in the elderly: Nuances and considerations.

Neurourol Urodyn 2022 May 29. Epub 2022 May 29.

Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA.

Introduction: Overactive bladder (OAB) disproportionally affects older adults in both incidence and severity. OAB pharmacotherapy is often problematic in the elderly due to polypharmacy, adverse side effect profiles and contraindications in the setting of multiple comorbidities, and concerns regarding the risk of incident dementia with anticholinergic use. The burden of OAB in older patients coupled with concerns surrounding pharmacotherapy options should motivate optimization of nonpharmacologic therapies in this population. Read More

View Article and Full-Text PDF

Discovery and characterization of a potent activator of the BK channel that relives overactive bladder syndrome in rats.

Eur J Pharmacol 2022 Jul 27;927:175055. Epub 2022 May 27.

School of Life Sciences, Gwangju Institute of Science and Technology (GIST), Gwangju, 61005, Republic of Korea; Center for AI-applied High Efficiency Drug Discovery, Gwangju Institute of Science and Technology (GIST), Gwangju, 61005, Republic of Korea. Electronic address:

The large-conductance Ca-activated K channel (BK channel) is involved in repolarizing the membrane potential and has a variety of cellular functions. The BK channel is highly expressed in bladder smooth muscle and mediates muscle relaxation. Compounds that activate the BK channel have therapeutic potential against pathological symptoms associated with the overactivity of bladder smooth muscle. Read More

View Article and Full-Text PDF

Cost-effectiveness of prophylactic retropubic sling at the time of vaginal prolapse surgery.

Am J Obstet Gynecol 2022 May 26. Epub 2022 May 26.

Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, IL.

Background: Prophylactic midurethral sling placement at the time of prolapse repair significantly reduces the risk for de novo stress urinary incontinence, but it is associated with some small but significant morbidities. Because there has not been a standardized approach to midurethral sling utilization, decision analysis provides a method to evaluate the cost and effectiveness associated with varying midurethral sling placement strategies in addressing the risk for de novo stress urinary incontinence.

Objective: We aimed to compare the cost effectiveness of the 3 midurethral sling utilization strategies in treating de novo stress urinary incontinence 1 year after vaginal prolapse repair. Read More

View Article and Full-Text PDF

Efficacy of 3 Tesla Functional Magnetic Stimulation for the Treatment of Female Urinary Incontinence.

J Clin Med 2022 May 16;11(10). Epub 2022 May 16.

Department of Obstetrics and Gynecology, Del Ponte Hospital, University of Insubria, 21100 Varese, Italy.

Functional magnetic stimulation (FMS) is a new technique for the conservative treatment of Urinary incontinence (UI), based on magnetic induction. It induces controlled depolarization of the nerves, resulting in pelvic muscle contraction and sacral S2-S4 roots neuromodulation. The aim of this study was to assess the efficacy of the new 3 Tesla FMS chair, both in patients with pure stress urinary incontinence (SUI) and in women with pure overactive bladder (OAB) symptoms. Read More

View Article and Full-Text PDF

Home-based transcutaneous tibial nerve stimulation for overactive bladder syndrome: a randomized, controlled study.

Int Urol Nephrol 2022 May 27. Epub 2022 May 27.

Assuta Medical Center, POB 229, 9093500, Bet Horon, Israel.

Purpose: Transcutaneous posterior tibial nerve stimulation (TPTNS) for the treatment of overactive bladder syndrome (OAB), with or without urge urinary incontinence (UUI) using electrodes imbedded in the fabric of a conventional sock and an attachable battery-operated stimulation device (ZIDA-Exodus Innovations, Sufa, Israel), was compared for effectiveness and safety to a sham procedure in a prospective, blinded, randomized, controlled trial.

Methods: Forty patients with diagnosed with OAB were recruited from a single site. There were two groups: a treatment group (21 patients, mean age 64), which used an active ZIDA activation device (ZIDA) and a sham control group (SCG, 19 patients, mean age 72) randomized in a 1:1 ratio. Read More

View Article and Full-Text PDF